New Insights into Pseudomonas aeruginosa Pathogenesis
A special issue of Pathogens (ISSN 2076-0817). This special issue belongs to the section "Bacterial Pathogens".
Deadline for manuscript submissions: 31 July 2024 | Viewed by 221
Special Issue Editors
Interests: animal models of acute and chronic pseudomonas aeruginosa lung infection; cystic fibrosis; host defense; inflammatory marker; immune response; co-morbiditie; outcomes of HIV infection; cellular and metabolic pathways
Special Issue Information
Dear Colleagues,
Pseudomonas aeruginosa is a Gram-negative bacterium that ubiquitously exists in the environment. There are many different types of Pseudomonas and the most common cause of opportunistic infections in humans is P. aeruginosa. P. aeruginosa is a known causative agent of acute, chronic and HAI infections. In recent years, there has been a strong emergence of antibiotic resistance strains that can have dire consequences on public health. My recent work has focused on investigating novel targets to enhance host immunity. Due to the prevalence of highly resistance microbials, there is an overarching need to (i) understand host–pathogen interactions and the factors utilized by the pathogen to attenuate host defense and establish infection and (ii) identifying host factors that can be pharmacologically targeted as a supplemental therapy, in addition to current anti-microbial treatment regimens. One such target that we have studied extensively is peroxisome proliferator-activated receptor gamma (PPARg). It is the downstream effector of lipid mediators such as prostaglandin D2 (PGD2). We have shown that PPARg and its downstream targets are compromised during acute and chronic lung infections. Currently, PPARγ agonists are a part of treatment regimens associated with cystic fibrosis. Directing therapeutics towards PPARg and its effector molecules can improve morbidity and mortality associated with infectious pneumonia, by simultaneously targeting inflammation, host defense and bacterial burden.
Dr. Brahmchetna Bedi
Dr. Susu Zughaier
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- P. aeruginosa
- quorum sensing
- PPARgamma
- host defense
- host–pathogen interactions
- paraoxanase
- cystic fibrosis
- ER stress
- inflammation
- antimicrobial peptide
- primary epithelial cells
